Developer docs
API playgroundTry for free, no card

Search company profiles

Gene Tools

Full company profile

uuid000oqaj

Namestring
Gene Tools
Legal namestring
Gene Tools, LLC
Websiteurl
gene-tools.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Gene Tools, LLC is a privately held Oregon-based company founded in 1997 that manufactures and sells Morpholino antisense oligos — short (~25 subunit) phosphorodiamidate morpholino oligomers (PMOs) that use an RNase H-independent steric blocking mechanism to knock down gene expression, modify RNA splicing, and inhibit miRNA activity. Its proprietary portfolio includes standard Morpholinos, Vivo-Morpholinos (octa-guanidine dendrimer conjugates covered by US Patent 7,935,816) for in vivo delivery to adult animals, peptide-conjugated Morpholinos (PPMOs), the Endo-Porter endosomal-escape delivery reagent, and HPLC purification services for high-purity oligos intended for conjugate work.

The company sells primarily through a self-service online storefront (store.gene-tools.com) with unit-based pay-as-you-go pricing, supplemented by direct Ph.D.-level customer support that provides free oligo design, experiment consultation, and troubleshooting. Customers are predominantly academic developmental biology labs (zebrafish, Xenopus, chick, sea urchin models) and pharmaceutical/biotech drug discovery groups using Morpholinos for target validation and exon-skipping research, with four FDA-approved PMO drugs (eteplirsen, casimersen, golodirsen, viltolarsen) validating the platform. Gene Tools maintains a publications database of over 12,256 citations and, as of October 2025, has a non-exclusive collaboration with Ajinomoto Bio-Pharma Services to route customers from research-grade PMO synthesis into GLP/GMP manufacturing for clinical programs. The firm is privately held with no disclosed funding rounds and 11–50 employees.

Short descriptiontext

Gene Tools manufactures Morpholino antisense oligos (PMOs) and delivery reagents — including proprietary Vivo-Morpholinos and PPMOs — for academic and pharmaceutical researchers conducting gene knockdown, splice modification, and exon-skipping studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhilomath, United States
HQ citystring
Philomath
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotides, morpholino synthesis, gene knockdown reagents, RNA splicing modification, oligonucleotide delivery reagents
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antisense Oligonucleotide Reagents
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Morpholino Oligo Sales
TypeOne Time License
Description

Gene Tools generates revenue through the sale of Morpholino antisense oligos in various forms including standard Morpholinos, Vivo-Morpholinos, Peptide-Conjugated Morpholinos (PPMOs), and associated delivery reagents like Endo-Porter. Products are sold in different quantities (400, 2000, 10,000 nmole) with pricing tiers for large-scale orders. The company also offers custom oligo design services as part of the product offering.

gene-tools.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales
Pricing details3 tiers
1Standard Morpholino oligos with quantity-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing varies by quantity and scale. Large scale orders have reduced pricing. Contact for quote on custom synthesis or large quantities.

gene-tools.com
2Vivo-Morpholinos in 400, 2000, and 10,000 nmole quantities
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Three standard quantities available - 400 nmole (approximately 16 injections at 25 nmole per 20g mouse at 12.5 mg/kg), 2000 nmole (approximately 80 injections), 10,000 nmole (approximately 400 injections). For syntheses greater than 10,000 nmol contact Customer Support.

gene-tools.com
3HPLC Purification add-on service
ModelOtherBilling cadencePay-as-you-go
Notes

High purity oligos recommended for oligo conjugates - available as add-on purification service.

gene-tools.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gene Tools manufactures and sells Morpholino antisense oligonucleotides (PMOs) and related delivery reagents used by researchers to knock down gene expression, modify RNA splicing, and inhibit miRNA activity. Core offerings include standard Morpholino Antisense Oligos, Vivo-Morpholinos for in vivo delivery, Peptide-Conjugated Morpholinos (PPMOs), and the Endo-Porter delivery reagent, complemented by free oligo design assistance from Ph.D.-level scientists and HPLC purification services for high-purity oligos.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 12,000 scientific publications using Morpholinos maintained in online browsable database
+1 more record
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Gene Tools and Ajinomoto Bio-Pharma Services announced a non-exclusive collaboration on October 21, 2025, to broaden access to phosphorodiamidate morpholino oligomers (PMOs) for treating genetic diseases such as Duchenne muscular dystrophy (DMD). Under the agreement, Gene Tools provides pre-purified PMO synthesis for early-stage research while Ajinomoto Bio-Pharma handles purification, quality control, and large-scale GLP/GMP manufacturing, creating a seamless pathway from early research to clinical development.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

IDT is a leading manufacturer of custom oligonucleotides (DNA, RNA, antisense) for research and diagnostics, with a global catalog and GMP capabilities. It is the closest direct competitor to Gene Tools in research-grade custom oligo supply, with substantially greater scale (owned by Danaher).

TypeBroad incumbent
Description

Sarepta commercializes FDA-approved Morpholino-based exon-skipping drugs (eteplirsen, casimersen, golodirsen) for Duchenne muscular dystrophy. It validates the Morpholino chemistry but is a downstream therapeutics player rather than a research-reagent competitor.

TypeDirect peer
Description

Bio-Synthesis is a custom oligonucleotide manufacturer offering modified oligos, antisense, and aptamers for research and diagnostic applications. It is a smaller-scale direct competitor in custom antisense oligo production.

TypeDirect peer
Description

Eurofins Genomics manufactures custom oligos, primers, and synthetic RNA products for academic and pharma research globally. It competes with Gene Tools on custom oligonucleotide synthesis for research customers.

TypeBroad incumbent
Description

Wave develops stereopure oligonucleotide therapeutics using PRISM chemistry, including exon-skipping programs for DMD and Huntington's. It is a broad incumbent in therapeutic antisense oligos, overlapping with Morpholino use cases in neuromuscular diseases.

TypeDirect peer
Description

TriLink manufactures modified mRNA, oligonucleotides, and nucleic acid analogs for research and therapeutic applications, including GMP-grade synthesis. It overlaps with Gene Tools on oligonucleotide chemistry and increasingly on GMP oligonucleotide supply via its Maravai LifeSciences parent.

TypeOthers
Description

Aji Bio-Pharma is Gene Tools' GMP manufacturing partner under the October 2025 collaboration and a leading CDMO for oligonucleotide and peptide synthesis. It is an enabling ecosystem participant rather than a competitor.

TypeDirect peer
Description

Biosearch Technologies designs and manufactures custom oligonucleotides, fluorescent probes, and qPCR assays for genomics research. It is a direct competitor in the custom research-oligo market served by Gene Tools.

9Nippon Shinyaku
TypeEmerging player
Description

Nippon Shinyaku developed viltolarsen (Viltepso), an FDA-approved Morpholino-based exon-skipping drug for DMD. It is a regional/emerging therapeutics player in the same Morpholino chemistry but focused on clinical/commercial supply rather than research reagents.

TypeBroad incumbent
Description

Ionis is the leading antisense oligonucleotide therapeutics company, with a broad ASO pipeline and commercial products. It is a broader incumbent in antisense chemistry — adjacent to Morpholinos — and competes for pharma R&D dollars in nucleic-acid therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gene Tools

Antisense Oligonucleotide Reagentsgene-tools.com

Gene Tools manufactures Morpholino antisense oligos (PMOs) and delivery reagents — including proprietary Vivo-Morpholinos and PPMOs — for academic and pharmaceutical researchers conducting gene knockdown, splice modification, and exon-skipping studies.

What Gene Tools does

Gene Tools, LLC is a privately held Oregon-based company founded in 1997 that manufactures and sells Morpholino antisense oligos — short (~25 subunit) phosphorodiamidate morpholino oligomers (PMOs) that use an RNase H-independent steric blocking mechanism to knock down gene expression, modify RNA splicing, and inhibit miRNA activity. Its proprietary portfolio includes standard Morpholinos, Vivo-Morpholinos (octa-guanidine dendrimer conjugates covered by US Patent 7,935,816) for in vivo delivery to adult animals, peptide-conjugated Morpholinos (PPMOs), the Endo-Porter endosomal-escape delivery reagent, and HPLC purification services for high-purity oligos intended for conjugate work.

The company sells primarily through a self-service online storefront (store.gene-tools.com) with unit-based pay-as-you-go pricing, supplemented by direct Ph.D.-level customer support that provides free oligo design, experiment consultation, and troubleshooting. Customers are predominantly academic developmental biology labs (zebrafish, Xenopus, chick, sea urchin models) and pharmaceutical/biotech drug discovery groups using Morpholinos for target validation and exon-skipping research, with four FDA-approved PMO drugs (eteplirsen, casimersen, golodirsen, viltolarsen) validating the platform. Gene Tools maintains a publications database of over 12,256 citations and, as of October 2025, has a non-exclusive collaboration with Ajinomoto Bio-Pharma Services to route customers from research-grade PMO synthesis into GLP/GMP manufacturing for clinical programs. The firm is privately held with no disclosed funding rounds and 11–50 employees.

Gene Tools firmographics

Firmographics
Name
Gene Tools
Legal name
Gene Tools, LLC
Website
https://gene-tools.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
Gene Tools manufactures Morpholino antisense oligos (PMOs) and delivery reagents — including proprietary Vivo-Morpholinos and PPMOs — for academic and pharmaceutical researchers conducting gene knockdown, splice modification, and exon-skipping studies.
Ownership category
akta.pro rank

Gene Tools industry classification

Industry
Product category
Antisense Oligonucleotide Reagents
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotides
  • Morpholino synthesis
  • Gene knockdown reagents
  • RNA splicing modification
  • Oligonucleotide delivery reagents

Where Gene Tools is headquartered

Location

Headquarters

HQ city
Philomath
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Gene Tools business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Morpholino Oligo Sales: Gene Tools generates revenue through the sale of Morpholino antisense oligos in various forms including standard Morpholinos, Vivo-Morpholinos, Peptide-Conjugated Morpholinos (PPMOs), and associated delivery reagents like Endo-Porter. Products are sold in different quantities (400, 2000, 10,000 nmole) with pricing tiers for large-scale orders. The company also offers custom oligo design services as part of the product offering.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Morpholino oligos with quantity-based pricing
Unit PricingPay-as-you-goVivo-Morpholinos in 400, 2000, and 10,000 nmole quantities
OtherPay-as-you-goHPLC Purification add-on service

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Gene Tools product offering

Product offering

Core offering

Gene Tools manufactures and sells Morpholino antisense oligonucleotides (PMOs) and related delivery reagents used by researchers to knock down gene expression, modify RNA splicing, and inhibit miRNA activity. Core offerings include standard Morpholino Antisense Oligos, Vivo-Morpholinos for in vivo delivery, Peptide-Conjugated Morpholinos (PPMOs), and the Endo-Porter delivery reagent, complemented by free oligo design assistance from Ph.D.-level scientists and HPLC purification services for high-purity oligos.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Over 12,000 scientific publications using Morpholinos maintained in online browsable database
  • +1 more outcomes

Companies that use Gene Tools

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Gene Tools technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Gene Tools partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ajinomoto Bio-Pharma Services (Aji Bio-Pharma)coreStrategic or Co-development Partner · 21 October 2025Gene Tools and Ajinomoto Bio-Pharma Services announced a non-exclusive collaboration on October 21, 2025, to broaden access to phosphorodiamidate morpholino oligomers (PMOs) for treating genetic diseases such as Duchenne muscular dystrophy (DMD). Under the agreement, Gene Tools provides pre-purified PMO synthesis for early-stage research while Ajinomoto Bio-Pharma handles purification, quality control, and large-scale GLP/GMP manufacturing, creating a seamless pathway from early research to clinical development.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Gene Tools competitors and assessment

Company assessment

Direct peers

  • Integrated DNA Technologies (IDT): IDT is a leading manufacturer of custom oligonucleotides (DNA, RNA, antisense) for research and diagnostics, with a global catalog and GMP capabilities. It is the closest direct competitor to Gene Tools in research-grade custom oligo supply, with substantially greater scale (owned by Danaher).
  • Bio-Synthesis Inc. Bio-Synthesis is a custom oligonucleotide manufacturer offering modified oligos, antisense, and aptamers for research and diagnostic applications. It is a smaller-scale direct competitor in custom antisense oligo production.
  • Eurofins Genomics: Eurofins Genomics manufactures custom oligos, primers, and synthetic RNA products for academic and pharma research globally. It competes with Gene Tools on custom oligonucleotide synthesis for research customers.
  • TriLink BioTechnologies: TriLink manufactures modified mRNA, oligonucleotides, and nucleic acid analogs for research and therapeutic applications, including GMP-grade synthesis. It overlaps with Gene Tools on oligonucleotide chemistry and increasingly on GMP oligonucleotide supply via its Maravai LifeSciences parent.
  • LGC Biosearch Technologies: Biosearch Technologies designs and manufactures custom oligonucleotides, fluorescent probes, and qPCR assays for genomics research. It is a direct competitor in the custom research-oligo market served by Gene Tools.

Broad incumbents

  • Sarepta Therapeutics: Sarepta commercializes FDA-approved Morpholino-based exon-skipping drugs (eteplirsen, casimersen, golodirsen) for Duchenne muscular dystrophy. It validates the Morpholino chemistry but is a downstream therapeutics player rather than a research-reagent competitor.
  • Wave Life Sciences: Wave develops stereopure oligonucleotide therapeutics using PRISM chemistry, including exon-skipping programs for DMD and Huntington's. It is a broad incumbent in therapeutic antisense oligos, overlapping with Morpholino use cases in neuromuscular diseases.
  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide therapeutics company, with a broad ASO pipeline and commercial products. It is a broader incumbent in antisense chemistry — adjacent to Morpholinos — and competes for pharma R&D dollars in nucleic-acid therapeutics.

Others

  • Ajinomoto Bio-Pharma Services: Aji Bio-Pharma is Gene Tools' GMP manufacturing partner under the October 2025 collaboration and a leading CDMO for oligonucleotide and peptide synthesis. It is an enabling ecosystem participant rather than a competitor.

Emerging players

  • Nippon Shinyaku: Nippon Shinyaku developed viltolarsen (Viltepso), an FDA-approved Morpholino-based exon-skipping drug for DMD. It is a regional/emerging therapeutics player in the same Morpholino chemistry but focused on clinical/commercial supply rather than research reagents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Gene Tools social profiles

Digital presence

Gene Tools financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gene Tools leadership team

Management profile

Number of profiles

Profiles2 records

Gene Tools funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gene Tools M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gene Tools

What does Gene Tools do?

Gene Tools manufactures and sells Morpholino antisense oligonucleotides (PMOs) and related delivery reagents used by researchers to knock down gene expression, modify RNA splicing, and inhibit miRNA activity. Core offerings include standard Morpholino Antisense Oligos, Vivo-Morpholinos for in vivo delivery, Peptide-Conjugated Morpholinos (PPMOs), and the Endo-Porter delivery reagent, complemented by free oligo design assistance from Ph.D.-level scientists and HPLC purification services for high-purity oligos.

Is Gene Tools a public or private company?

Gene Tools is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Gene Tools founded?

Gene Tools was founded in 1997. It employs 1 to 10 people.

Where is Gene Tools based?

Gene Tools is headquartered in Philomath, United States, in the North America region.

How does Gene Tools make money?

One revenue line is on record: morpholino Oligo Sales.

Who are Gene Tools's main competitors?

Direct peers on record are Integrated DNA Technologies (IDT), Bio-Synthesis Inc., Eurofins Genomics, TriLink BioTechnologies and LGC Biosearch Technologies. Broad incumbents are Sarepta Therapeutics, Wave Life Sciences and Ionis Pharmaceuticals. Ajinomoto Bio-Pharma Services is listed as an others. Nippon Shinyaku is listed as an emerging player.

Does Gene Tools have an API?

No public API is recorded for Gene Tools.

What industry is Gene Tools in?

Gene Tools's product category is Antisense Oligonucleotide Reagents. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals